Cited by 1,487Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Open access

Colditz, Graham A., Hankinson, Susan E., Hunter, David J., Willett, Walter C., Manson, JoAnn E., Stampfer, Meir J., Hennekens, Charles, Rosner, Bernard, Speizer, Frank E.·1995·New England Journal of Medicine

DOI 10.1056/nejm199506153322401

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. METHODS: To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breast cancer. RESULTS: The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. CONCLUSIONS: The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women. The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.

Integrity signals

Registry

Crossref · 10.1056/nejm199506153322401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Variations in mortality by weight among 750,000 men and women
Lew, E. A., & Garfinkel, L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90119-x · Cited by 1,169
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., SPICER, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,009
TEST OF THE NATIONAL DEATH INDEX
Stampfer, M. J., Willett, W. C., Speizer, F. E., DYSERT, D. C., LIPNICK, R. J., ROSNER, B. A., & Hennekens, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 791
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 658
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Bergkvist, L., Adami, H., Persson, I. R., Hoover, R. N., & Schairer, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210505 · Cited by 612
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 580
THE EPIDEMIOLOGY OF SERUM SEX HORMONES IN POSTMENOPAUSAL WOMEN
Cauley, J. A., Gutai, J. P., Kuller, L. H., LEDONNE, D., & POWELL, J. G. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115234 · Cited by 485
Biologic Effects of Transdermal Estradiol
Chetkowski, R. J., Meldrum, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P., & Judd, H. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142505 · Cited by 482
Biologic effects of transdermal estradiol
Chetkowski, R. J., Meldrum, D., & Ka, S. (1987) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(87)90325-0 · Cited by 467

Show all 32 references

Research works printed but not linked: 4

Feinleib M, 1968, J Natl Cancer Inst, 41, 315
Committee on the relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives & breast cancer. Washington, D.C.: National Academy Press, 1991.
Gambrell RD, 1983, Obstet Gynecol, 62, 435
Rose DP, 1977, Obstet Gynecol, 49, 80

Sorted by citations

Items 101–200 of 999

Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women
Guetta, V., & Cannon, R. O. (1996) · Circulation · doi:10.1161/01.cir.93.10.1928 · Cited by 207
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model
Santen, R. J., Boyd, N. F., Chlebowski, R. T., Cummings, S. R., Cuzick, J. M., Dowsett, M., Easton, D. F., Forbes, J., Key, T., Hankinson, S. E., et al. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0045 · Cited by 202
“However, other observational studies suggest that especially long estrogen use of O20 years is associated with some breast cancer increase (Colditz et al. 1995, Chen et al. 2006b).”
Background
Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
Willis, D. B., Calle, E. E., Miracle-McMahill, H. L., & Heath, C. W. (1996) · Cancer Causes & Control · doi:10.1007/bf00052671 · Cited by 201
Is hormone replacement therapy protective for hand and knee osteoarthritis in women?: The Chingford study
Spector, T. D., Nandra, D., Hart, D. J., & Doyle, D. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.7.432 · Cited by 200
Design of surface-modified poly(d,l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone
Choi, S. W., & Kim, J. H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.06.003 · Cited by 197
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women???s Health Initiative Randomized Controlled Trial
Writing Group for the Women’s Health Initiative Investigators (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200211000-00019 · Cited by 196
Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis
Kobayashi, M., Ikeda, K., Saitoh, S., Suzuki, F., Tsubota, A., Suzuki, Y., Arase, Y., Murashima, N., Chayama, K., & Kumada, H. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11 · Cited by 245
Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer
Tamimi, R. M., Spiegelman, D. L., Smith‐Warner, S. A., Wang, M., Pazaris, M. J., Willett, W. C., Eliassen, A. H., & Hunter, D. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww145 · Cited by 194
The Role of Hormone Replacement Therapy in the Risk for Breast Cancer and Total Mortality in Women with a Family History of Breast Cancer
Sellers, T. A., Mink, P. J., Cerhan, J. R., Zheng, W., Anderson, K. E., Kushi, L. H., & Folsom, A. R. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-11-199712010-00004 · Cited by 188
“Despite the evidence in the literature that HRT may be associated with a modestly increased risk for breast cancer (14), total mortality rates are decreased with HRT use (8, 14, 15).”
Background
Randomized, Double-Blind, Placebo-Controlled Study on Effects of Raloxifene and Hormone Replacement Therapy on Plasma NO Concentrations, Endothelin-1 Levels, and Endothelium-Dependent Vasodilation in Postmenopausal Women
Saitta, A., Altavilla, D., Cucinotta, D., Morabito, N., Frisina, N., Corrado, F., D’Anna, R., Lasco, A., Squadrito, G., Gaudio, A., et al. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0901.095565 · Cited by 188
Biomedical applications of bisphosphonates
Giger, E. V., Castagner, B., & Leroux, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.032 · Cited by 192
Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density.
Persson, I., Thurfjell, E., & Holmberg, L. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3201 · Cited by 186
Predicting the Cumulative Risk of False-Positive Mammograms
Christiansen, C. L. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1657 · Cited by 183
Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis
Garg, P. P. (1998) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(98)00139-2 · Cited by 183
“The risk of breast cancer among users of HRT recently was examined in a large cohort study that demonstrated a 40–50% increase in risk of breast cancer among women who used estrogens more than 10 years.(9) Although it has been shown that use of premenopausal progestins in the form of oral contraception decreases the i…”
BackgroundResult
Postmenopausal estrogen and progestin use in relation to breast cancer risk.
Newcomb, P. A., Titus-Ernstoff, L. T., Egan, K. M., Trentham‐Dietz, A., Baron, J. A., Storer, B. E., Willett, W. C., & Stampfer, M. J. (2002) · PubMed · Cited by 182
Risk Factors of Breast Cancer
Anothaisintawee, T., Wiratkapun, C., Lerdsitthichai, P., Kasamesup, V., Wongwaisayawan, S., Srinakarin, J., Hirunpat, S., Woodtichartpreecha, P., Boonlikit, S., Teerawattananon, Y., et al. (2013) · Asia Pacific Journal of Public Health · doi:10.1177/1010539513488795 · Cited by 179
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 181
Structure−Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene
Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606352 · Cited by 177
Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- 2-(4-hydroxyphenyl)]benzo[b]thiophene: A Novel, Highly Potent, Selective Estrogen Receptor Modulator
Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Shetler, P. K., Cullinan, G. J., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970167b · Cited by 177
Hormone Replacement Therapy Regimens and Breast Cancer Risk
Weiss, L. K., Burkman, R. T., Cushing‐Haugen, K. L., Voigt, L. F., Simon, M. S., Daling, J. R., Norman, S. A., Bernstein, L., Ursin, G., Marchbanks, P. A., et al. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02502-4 · Cited by 176
Estimating the accuracy of screening mammography
Mushlin, A. I., Kouides, R. W., & Shapiro, D. E. (1998) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(97)00019-6 · Cited by 175
Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys1
Clarkson, T. B., Anthony, M. S., & Jerome, C. P. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4617 · Cited by 175
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Self-citation
Physiological Investigation of a Unique Extract of Black Cohosh ( Cimicifugae racemosae rhizoma ): A 6-Month Clinical Study Demonstrates No Systemic Estrogenic Effect
Liske, E., Hänggi, W., Zepelin, H. H., Boblitz, N., Wüstenberg, P. W., & Rahlfs, V. W. (2002) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/152460902753645308 · Cited by 171
Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy
Flesch‐Janys, D., Slanger, T. E., Mutschelknauss, E. J., Kropp, S., Obi, N., Vettorazzi, E., Braendle, W. L., Bastert, G., Hentschel, S., Berger, J., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23655 · Cited by 171
“The higher risk associated with EP therapy compared to mono-estrogen therapy has also been observed across different histological tumor types.(6,17,18) Several studies have investigated differences in risk by regimen, however, a higher risk for continuous than for cyclical EP therapy was found only in Scandinavian stu…”
Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study
Philipp, T., Anlauf, M., Distler, A., Holzgreve, H., Michaelis, J., & Wellek, S. (1997) · BMJ · doi:10.1136/bmj.315.7101.154 · Cited by 167
Risk Factors for Breast Cancer According to Family History of Breast Cancer
Colditz, G. A., ROSNER, B. A., & Speizer, F. E. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.6.365 · Cited by 166
Role of Quinoids in Estrogen Carcinogenesis
Bolton, J. L., Pisha, E., Zhang, F., & Qiu, S. (1998) · Chemical Research in Toxicology · doi:10.1021/tx9801007 · Cited by 166
Pharmacokinetics of raloxifene and its clinical application
Hochner‐Celnikier, D. (1999) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(98)00278-4 · Cited by 165
Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation
Kasugai, S., Fujisawa, R., Waki, Y., Miyamoto, K., & Ohya, K. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.936 · Cited by 162
“(1,2) A drug exhibiting the beneficial effects”
Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study
Squadrito, F., Altavilla, D., Crisafulli, A., Saitta, A., Cucinotta, D., Morabito, N., D’Anna, R., Corrado, F., Ruggeri, P., Frisina, N., et al. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00059-7 · Cited by 162
EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., et al. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00065-5 · Cited by 161
“[185] G.”
Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women — results of the Danish Osteoporosis Prevention Study
Mosekilde, L., Beck‐Nielsen, H., Sørensen, O. H., Nielsen, S. P., Charles, P., Vestergaard, P., Hermann, A. P., Gram, J., Hansen, T. B., Abrahamsen, B., et al. (2000) · Maturitas · doi:10.1016/s0378-5122(00)00158-4 · Cited by 160
“However, there was no trend towards an increase in the number of breast cancers, but previous studies have suggested that such an increase would first be expected after more than five years of HRT [26].”
Background
A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer
Hunter, D. (1997) · Carcinogenesis · doi:10.1093/carcin/18.11.2127 · Cited by 158
Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women
Roo, G. W. D. V.-D., Stehouwer, C. D. A., Meijer, P., Mijatovic, V., Kluft, C., Kenemans, P., Cohen, F. J., Watts, S. D., & Netelenbos, J. C. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.12.2993 · Cited by 158
“Estradiol, pmol/L 11 (9; 14) 12 (7; 20) 11 (7; 19) 15 (8; 27) 8 (6; 11)”
Changing Concepts: Menopausal Hormone Therapy and Breast Cancer
Chlebowski, R. T., & Anderson, G. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs014 · Cited by 161
“Parallel analyses in the Nurses’ Health Study cohort found that estrogen alone and estrogen plus progestin were both associated with an increased risk of breast cancer (9).”
BackgroundMethod
Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells
Foidart, J.-M., Colin, C., Denoo, X., Desreux, J., Béliard, A., Fournier, S., & Lignieres, B. D. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00042-9 · Cited by 155
“5 mg/d) and progesterone (25 mg/d); or [4] placebo.”
Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models
Ke, H. Z., Paralkar, V. M., GRASSER, W. A., Crawford, D. T., Qi, H., Simmons, H. A., Pirie, C. M., Chidsey-Frink, K. L., Owen, T. A., Smock, S. L., et al. (1998) · Endocrinology · doi:10.1210/endo.139.4.5902 · Cited by 161
Occupational and nonoccupational factors in job satisfaction and psychological distress among nurses
Decker, F. H. (1997) · Research in Nursing & Health · doi:10.1002/(sici)1098-240x(199710)20:5 · Cited by 143
Breast cancer and hormone replacement therapy.
LaCroix, A. Z., & Burke, W. (1990) · PubMed · Cited by 155
Soy Isoflavones: Are They Useful in Menopause?
Vincent, A., & Fitzpatrick, L. A. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.11.1174 · Cited by 153
Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
Kerlikowske, K. M., Miglioretti, D. L., Buist, D. S. M., Walker, R. L., & Carney, P. A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm111 · Cited by 154
Identifying patient preferences for communicating risk estimates: A descriptive pilot study
Fortin, J. M., Hirota, L. K., Bond, B., O'Connor, A. M. C., & Col, N. F. (2001) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-1-2 · Cited by 153
“For example, the decision of whether or not to use hormone replacement therapy (HRT) after menopause involves weighing the benefits of treatment (immediate symptom relief, [12] decreased future risk of hip fracture [13] and possible decreased risk of coronary heart disease [14,15]) against its risks (increased future…”
Background
Combined Estrogen and Testosterone Use and Risk of Breast Cancer in Postmenopausal Women
Tamimi, R. M., Hankinson, S. E., Chen, W. Y., ROSNER, B. A., & Colditz, G. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.14.1483 · Cited by 150
“09).(27) The results of the current analysis suggest that E&T therapy is associated with a greater risk of breast cancer compared with estrogen-only therapy.”
Result
Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma
Daling, J. R., Malone, K. E., Doody, D. R., Voigt, L. F., Bernstein, L., Coates, R. J., Marchbanks, P. A., Norman, S. A., Weiss, L. K., Ursin, G., et al. (2002) · Cancer · doi:10.1002/cncr.10984 · Cited by 151
“Studies that have included women who were diagnosed during the 1990s and, hence, that had adequate numbers of women with long-term exposure have shown an increased risk for breast carcinoma among women using combined therapy.(15,16,25,26) The results of the current study, in agreement with three TABLE 4 Relation of Ho…”
Result
Raloxifene
Clemett, D., & Spencer, C. M. (2000) · Drugs · doi:10.2165/00003495-200060020-00013 · Cited by 150
“[10] Use of estrogens is also associated with an increased risk of endometrial[11-13] and breast cancer.[14-16] Although addition of a progestin to”
Dietary Carbohydrates, Fiber, and Breast Cancer Risk
Holmes, M. D. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh112 · Cited by 144
“We have previously reported associations between several factors in table 1 and risk of breast cancer: a decreased risk of parity (17) and increased risks of benign breast disease (18); alcohol intake (19); and, among postmenopausal women, use of hormone replacement therapy (19, 20) as well as overweight and weight ga…”
Background
Female hepatology: Favorable role of estrogen in chronic liver disease with hepatitis B virus infection
Shimizu, I. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i32.4295 · Cited by 145
Bisphenol-A content of resin monomers and related degradation products
Schmalz, G., Preiß, A., & Arenholt‐Bindslev, D. (1999) · Clinical Oral Investigations · doi:10.1007/s007840050088 · Cited by 146
Postmenopausal Hormone Therapy and Risk of Developing Urinary Incontinence
Grodstein, F., Lifford, K. L., Resnick, N. M., & Curhan, G. C. (2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000107290.33034.6f · Cited by 146
Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
Sourander, L., Rajala, T., Räihä, I. J., Mäkinen, J. I., Erkkola, R., & Helenius, H. Y. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05066-1 · Cited by 146
Explaining the Relation Between Education and Postmenopausal Breast Cancer
Heck, K. E., & Pamuk, E. R. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009114 · Cited by 144
Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer study
Bakken, K. S., Alsaker, E., Eggen, A. E., & Lund, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20389 · Cited by 144
Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale
U.S. Preventive Services Task Force* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-10-200211190-00013 · Cited by 144
“The effects of long-term HRT use on breast cancer mortality in two good-quality cohort studies are conflicting (11, 12).”
Background
Bone-Specific Drug Delivery Systems
Hirabayashi, H., & Fujisaki, J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00002 · Cited by 143
Treatment of menopausal symptoms: what shall we do now?
Hickey, M., Davis, S. R., & Sturdee, D. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66519-1 · Cited by 145
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate
Frolik, C. A. (1996) · Bone · doi:10.1016/8756-3282(96)00085-3 · Cited by 143
Effect of osteoporosis medications on fracture healing
Hegde, V. V., Jo, J. E., Andreopoulou, P., & Lane, J. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3331-7 · Cited by 142
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.
Holli, K. A., Isola, J., & Cuzick, J. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3115 · Cited by 142
Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk
Col, N. F., Hirota, L. K., Orr, R. K., Erban, J. K., Wong, J. B., & Lau, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2357 · Cited by 139
A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women
Prestwood, K. M., Gunness, M. E., Muchmore, D. B., Lu, Y., Wong, M., & Raisz, L. G. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6654 · Cited by 144
Hormone replacement therapy and breast cancer: a qualitative review
Bush, T. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01453-3 · Cited by 138
“Figure 4 presents the risk estimates for breast cancer by duration of hormone use for all cohort studies which evaluated the risk by duration.(42,43,50,59,61,62,92,93) Most studies included in Figure 4 presented estimates for any hormone use or all hormone use, while three(43,61,92) provided separate estimates for est…”
Background
Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Miller, V. M., Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Hodis, H. N., Løbo, R. A., Manson, J. E., Merriam, G. R., Naftolin, F. N., et al. (2009) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-009-9104-y · Cited by 139
“Furthermore, MHT was reported in both observational studies and randomized clinical trials to significantly reduce the risk of osteoporosis-related fractures [12, 23, 65] and colon cancer [27] while increasing age-adjusted incidence of breast cancer by about 20% [6, 17, 76], but decreasing breast cancer mortality by o…”
Background
Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma
Chen, W. Y., Hankinson, S. E., Schnitt, S. J., ROSNER, B. A., Holmes, M. D., & Colditz, G. A. (2004) · Cancer · doi:10.1002/cncr.20499 · Cited by 133
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K., Paganini‐Hill, A., Wan, P. C., & Pike, M. C. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200007000-00022 · Cited by 135
Endogenous sex hormones and subsequent breast cancer in premenopausal women
Micheli, A., Muti, P. C., Secreto, G., Krogh, V., Meneghini, E., Venturelli, E., Sieri, S., Pala, V. M., & Berrino, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20403 · Cited by 135
What is osteoporosis?
Christodoulou, C., & Cooper, C. C. (2003) · Postgraduate Medical Journal · doi:10.1136/pmj.79.929.133 · Cited by 135
Causes of Alzheimer's disease.
Muñoz, D. G., & Feldman, H. (2000) · PubMed Central · Cited by 136
Estrogen Replacement Therapy After Coronary Angioplasty in Women
O’Keefe, J. H., Kim, S. C., Hall, R. R., Cochran, V. C., Lawhorn, S. L., & McCallister, B. D. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00443-3 · Cited by 135
Estrogen action: A historic perspective on the implications of considering alternative approaches
Jensen, E. V., Jacobson, H. I., Walf, A. A., & Frye, C. A. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.08.013 · Cited by 133
“For example, recent studies have further confirmed that the role of E2 to increase risk for breast cancer is widely recognized [73], and greater breast cancer risk has been shown to be associated with high serum E2 [74–77] and administration of E2 to postmenopausal women [78,79].”
Research on the menopause
Hulka, B. S., & Meirik, O. (1996) · Maturitas · doi:10.1016/0378-5122(95)00967-1 · Cited by 133
Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits
Bjarnason, N. H., Haarbo, J., Byrjalsen, I., Kauffman, R. F., & Christiansen, C. (1997) · Circulation · doi:10.1161/01.cir.96.6.1964 · Cited by 133
Psychosocial Factors, Sex Differences, and Atherosclerosis
Kaplan, J. R., Adams, M. R., Clarkson, T. B., Manuck, S. B., Shively, C. A., & Williams, J. K. (1996) · Psychosomatic Medicine · doi:10.1097/00006842-199611000-00008 · Cited by 132
PREVENTION OF BONE LOSS WITH ALENDRONATE IN POSTMENOPAUSAL WOMEN UNDER 60 YEARS OF AGE
Osking, D. A. H., Lair, C., Hristiansen, C. L. C., Avn, P. E. R., Asnich, R. I. W., Oss, P., Lung, M., Hompson, D. E. T., Aley, M. A. D., & Ateş, A. (1998) · Cited by 132
Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition
Huang, P.-H., Huang, C., Chen, M., Lee, Y.-T., Yue, C.-H., Wang, H., & Lin, H. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/376123 · Cited by 131
Coronary heart disease: an older woman's major health risk
WENGER, N. K. (1997) · BMJ · doi:10.1136/bmj.315.7115.1085 · Cited by 129
Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study.
Crisafulli, A., Marini, H. R., Bitto, A., Altavilla, D., Squadrito, G., Romeo, A., Adamo, E. B., Marini, R., D’Anna, R., Corrado, F., et al. (2004) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000109314.11228.e5 · Cited by 128
Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population
Kerlikowske, K. M., Miglioretti, D. L., Ballard-Barbash, R. R., Weaver, D. L., Buist, D. S. M., Barlow, W. E., Cutter, G., Geller, B. M., Yankaskas, B. C., Taplin, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.151 · Cited by 129
Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004
Hussain, S. K., Altieri, A., Sundquist, J., & Hemminki, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.23007 · Cited by 127
Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy
Titus-Ernstoff, L. T., Hatch, E. E., Hoover, R. N., Palmer, J. R., Greenberg, E. R., Ricker, W., Kaufman, R. H., Noller, K. L., Herbst, A. L., Colton, T., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1521 · Cited by 127
“A possible causal role for DES receives some support from evidence for an association between HRT and breast cancer risk (Colditz et al, 1995; CGHFBC, 1997; Schairer et al, 2000), generally with recent, long-term use; in contrast, DES exposure was brief, even for women with multiple exposed…”
Managing side effects in adjuvant endocrine therapy for breast cancer
Condorelli, R., & Vaz-Luís, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1520096 · Cited by 132
Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues: Highly Potent Selective Estrogen Receptor Modulators
Grese, T. A., Pennington, L. D., Sluka, J. P., Adrian, M. D., Cole, H. W., Fuson, T. R., Magee, D. E., Phillips, D. L., Rowley, E. R., Shetler, P. K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970688z · Cited by 126
Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy?
Wuttke, W., Jarry, H., Becker, T., Schultens, A., Christoffel, V., Gorkow, C., & Seidlová‐Wuttke, D. (2003) · Maturitas · doi:10.1016/s0378-5122(02)00344-4 · Cited by 125
“[2] Colditz GA, Hankinson SE, Hunter DJ, et al.”
Background
A Review of the Effectiveness of Cimicifuga racemosa (Black Cohosh) for the Symptoms of Menopause
Lieberman, S. (1998) · Journal of Women s Health · doi:10.1089/jwh.1998.7.525 · Cited by 123
Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model
Ke, H. Z., Chen, H. K., Simmons, H. A., Qi, H., Crawford, D. T., Pirie, C. M., Chidsey-Frink, K. L., Ma, Y. F., Jee, W. S. S., & Thompson, D. D. (1997) · Bone · doi:10.1016/s8756-3282(96)00313-4 · Cited by 123
Mechanisms of Cyclin-Dependent Kinase Inactivation by Progestins
Musgrove, E. A., Swarbrick, A., Lee, C. S. L., Cornish, A. L., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1812 · Cited by 123
“In contrast, while the effect of hormonal therapies on breast cancer risk has been controversial, there appears to be a slight increase in risk in recent or current users (7, 8), and in postmenopausal women the risk of breast cancer associated with estrogen use does not appear to be reduced by the addition of progesti…”
Background
One-carbon metabolism-related gene polymorphisms and risk of breast cancer
Suzuki, T., Matsuo, K., Hirose, K., Hiraki, A., Kawase, T., Watanabe, M., Yamashita, T., Iwata, H., & Tajima, K. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm295 · Cited by 119
Where Are We Going?
Santoro, N. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5765-1 · Cited by 122
Breast cancer risk factors in relation to breast density (United States)
Titus-Ernstoff, L. T., Tosteson, A. N. A., Kasales, C. J., Weiss, J. E., Goodrich, M., Hatch, E. E., & Carney, P. A. (2006) · Cancer Causes & Control · doi:10.1007/s10552-006-0071-1 · Cited by 122
“A prospective study of breast cancer risk also noted stronger HT effects in older women [37], although this is not always seen [36].”
Estrogens and breast cancer
Kim, J., & Münster, P. N. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.824 · Cited by 134
Recent trends in breast cancer mortality among white and black US women.
Chevarley, F. M., & White, E. (1997) · American Journal of Public Health · doi:10.2105/ajph.87.5.775 · Cited by 121
Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats1
Qu, Q., Zheng, H., Dahllund, J., Laine, A. M., Cockcroft, N., Peng, Z., Koskinen, M., Hemminki, K., Kangas, L., Väänänen, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.2.7342 · Cited by 120
Cancer Risk Associated with Subfertility and Ovulation Induction: A Review
Klip, H., Burger, C. W., Kenemans, P., & van Leeuwen, F. E. (2000) · Cancer Causes & Control · doi:10.1023/a:1008921211309 · Cited by 120
Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes
Deng, H., Li, J., Li, J.-L., Johnson, M. L., Gong, G., Davis, K. M., & Recker, R. R. (1998) · Human Genetics · doi:10.1007/s004390050872 · Cited by 118
“However, there are problems associated with long-term HRT, such as the possible increased risk of breast cancer and symptoms of breast tenderness and mood changes, etc. (Colditz et al. 1995; Selby and Peacock 1986).”
Background
Racial differences in premenopausal endogenous hormones
Pinheiro, S. P., Holmes, M. D., Pollak, M. N., Barbieri, R. L., & Hankinson, S. E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0944 · Cited by 119
“Some studies, although not all (52-55), suggest that the use of estrogen and progestins in hormone replacement therapy may increase breast cancer risk beyond that following use of estrogen alone (56-58).”
Background
Breast Cancer Screening in Older Women
Caplan, L. S., & Haynes, S. G. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04763.x · Cited by 119
Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7
Loprinzi, C. L., Levitt, R., Barton, D. L., Sloan, J. A., Dakhil, S. R., Nikcevich, D. A., Bearden, J. D., Mailliard, J. A., Tschetter, L. K., Fitch, T. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7324 · Cited by 119
Population aging and health
Butler, R. N. (1997) · BMJ · doi:10.1136/bmj.315.7115.1082 · Cited by 120
Mammographic Density Measured with Quantitative Computer-aided Method: Comparison with Radiologists' Estimates and BI-RADS Categories
Martin, K. E., Helvie, M. A., Zhou, C., Roubidoux, M. A., Bailey, J. E., Paramagul, C., Blane, C. E., Klein, K. A., Sonnad, S. S., & Chan, H. (2006) · Radiology · doi:10.1148/radiol.2402041947 · Cited by 117
Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial
Wong, W. W., Lewis, R. D., Steinberg, F. M., Murray, M. J., Cramer, M. A., Amato, P., Young, R. L., Barnes, S., Ellis, K. J., Shypailo, R. J., et al. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28001 · Cited by 119

Authors: Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Colditz, Graham A.
Hankinson, Susan E.
Willett, Walter C.
Manson, JoAnn E.
Stampfer, Meir J.
Hennekens, Charles
Rosner, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-06-15
Volume: 332
Issue: 24
Pages: 1589-1593
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199506153322401
OpenAlex: W2607238143
Cited by: 1,487
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 18 · 2014: 21 · 2013: 18 · 2012: 26
FWCI: 111.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 40956)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: breast cancer risk, hormone replacement therapy, estrogen therapy, progestins, estrogen plus progestin, duration of hormone use, age-related risk, breast cancer mortality, Nurses' Health Study
MeSH terms: Aged, Breast Neoplasms, Estrogens, Female, Follow-Up Studies, Humans, Middle Aged, Progestins, Prospective Studies, Risk, Risk Factors, Cohort Studies, Estrogen Replacement Therapy, Confidence Intervals, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks